INDICATIONS AND USAGE
as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase
as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
to reduce total-C and LDL-C in patients with homozygous
as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if, after an adequate trial of diet therapy, the following findings are present:
LDL-C remains 190 mg/dL or
LDL-C remains 160 mg/dL and:
there is a positive family history of premature
. TABLE 6. NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories
--------------------------------------------------------------------------------
Risk Category LDL Goal
(mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes
(mg/dL) LDL Level at Which to Consider Drug Therapy
(mg/dL)
